Publication | Closed Access

Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival

Cave TrialRatio Predicts SurvivalMedicineImmunologyTumor ImmunityColorectal CancerPathologyCancer TreatmentOncologyRadiation OncologyFinal Results